


ABSTRACT OF THE DISCLOSURE


Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula:

5


Sub  
A2



wherein  $W^1$  and  $W^2$  are  $-O-$ ,  $-S(=O)_t-$  or  $-N(R^3)-$ ;  $Y$  is  $=C(R^1_a)-$ , or  $-[N\Rightarrow(O)_k]-$ ;  $D$  is a group of partial Formulas (1.1.1) through (1.1.9):



10



where  $R^7$  is (a)  $-H$ ; (b)  $-(C_1-C_6)$  alkyl,  $-(C_2-C_6)$  alkenyl, or  $-(C_2-C_6)$  alkynyl; (c)  $-(CH_2)_u-(C_3-C_7)$  cycloalkyl; or (d) phenyl or benzyl;  $R^8$  is a mono- or bicyclic heterocycle; and

15  $J^1$  and  $J^2$  are a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic; wherein optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; and where N is selected, optionally a second carbon atom thereof may be replaced by a heteroatom selected from N, O, and S; or a

20

pharmaceutically acceptable salt thereof.